Literature DB >> 19416752

Clinical implication of estrogen-related receptor (ERR) expression in uterine endometrial cancers.

Jiro Fujimoto1, Eriko Sato.   

Abstract

Estrogen receptor (ER)alpha and ERbeta mRNAs levels decreased with clinical stage, myometrial invasion and dedifferentiation. On the other hand, ERRalpha mRNA levels and histoscores increased with clinical stage and myometrial invasion, regardless of dedifferentiation. ERRalpha can bind to the steroid receptor coactivator family without any ligands, and drive transcription activity of the target genes. The competitive interaction of ERRalpha/ER expression associated with the use of common cofactors during loosing estrogen dependency might cause their expression manner. The up-regulation of ERRalpha might be related to tumor growth and advancement in uterine endometrial cancers. It is speculated that ERRalpha is a candidate for prognostic factors in uterine endometrial cancer, although ERRs are not directly related to growth of uterine endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416752     DOI: 10.1016/j.jsbmb.2009.04.012

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  19 in total

Review 1.  The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis.

Authors:  Sang Jun Han; Bert W O'Malley
Journal:  Hum Reprod Update       Date:  2014-03-14       Impact factor: 15.610

2.  Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression.

Authors:  Ashley S Felix; Roslyn A Stone; Mamatha Chivukula; Robert Bowser; Anil V Parwani; Faina Linkov; Robert P Edwards; Joel L Weissfeld
Journal:  Int J Cancer       Date:  2012-01-03       Impact factor: 7.396

3.  A novel steroidal inhibitor of estrogen-related receptor alpha (ERR alpha).

Authors:  Sarah J Duellman; Joy M Calaoagan; Barbara G Sato; Richard Fine; Boris Klebansky; Wan-Ru Chao; Peter Hobbs; Nathan Collins; Lidia Sambucetti; Keith R Laderoute
Journal:  Biochem Pharmacol       Date:  2010-05-31       Impact factor: 5.858

Review 4.  Role of HIF-1α/ERRα in Enhancing Cancer Cell Metabolism and Promoting Resistance of Endometrial Cancer Cells to Pyroptosis.

Authors:  Pingping Su; Lirui Yu; Xiaodan Mao; Pengming Sun
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

5.  Effects of estrogen-related receptor alpha (ERRα) on proliferation and metastasis of human lung cancer A549 cells.

Authors:  Jian-Wei Huang; Bao-Zhang Guan; Liang-Hong Yin; Fan-Na Liu; Bo Hu; Qi-Yi Zheng; Fo-Lan Li; Ying-Xue Zhong; Yu Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

6.  Controversies in the management of endometrial carcinoma.

Authors:  Ying Zhang; Jian Wang
Journal:  Obstet Gynecol Int       Date:  2010-06-22

7.  Estrogen-related receptor α in normal adrenal cortex and adrenocortical tumors: involvement in development and oncogenesis.

Authors:  Saulo J A Felizola; Yasuhiro Nakamura; Xiao-Gang Hui; Fumitoshi Satoh; Ryo Morimoto; Keely M McNamara; Sanae Midorikawa; Shinichi Suzuki; William E Rainey; Hironobu Sasano
Journal:  Mol Cell Endocrinol       Date:  2012-10-30       Impact factor: 4.102

8.  Anti-tumor effect of estrogen-related receptor alpha knockdown on uterine endometrial cancer.

Authors:  Hiroshi Matsushima; Taisuke Mori; Fumitake Ito; Takuro Yamamoto; Makoto Akiyama; Tetsuya Kokabu; Kaori Yoriki; Shiori Umemura; Kyoko Akashi; Jo Kitawaki
Journal:  Oncotarget       Date:  2016-06-07

9.  miR-137/ERRα axis mediates chemoresistance of nasopharyngeal carcinoma cells.

Authors:  Fei Liu; Chunsheng Gao; Wenjuan Wang; Jing Hu; Zuofeng Huang; Meng Liang; Shuo Li
Journal:  J Cell Commun Signal       Date:  2021-07-01       Impact factor: 5.782

10.  ERRα protein is stabilized by LSD1 in a demethylation-independent manner.

Authors:  Julie Carnesecchi; Catherine Cerutti; Jean-Marc Vanacker; Christelle Forcet
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.